| Literature DB >> 26951089 |
Naoya Murakami1, Fumihiko Matsumoto2, Seiichi Yoshimoto3, Yoshinori Ito4, Taisuke Mori5, Takao Ueno6, Keisuke Tuchida7, Tairo Kashihara8, Kazuma Kobayashi9, Ken Harada10, Mayuka Kitaguchi11, Shuhei Sekii12, Rei Umezawa13, Kana Takahashi14, Koji Inaba15, Hiroshi Igaki16, Jun Itami17.
Abstract
BACKGROUND: The radiation field for patients with postoperative head and neck squamous cell carcinoma is narrower in our institution than in Western countries to reduce late radiation related toxicities. This strategy is at a risk of loco-regional or distant metastasis. However, because patients are more closely checked than in Western countries by every 1 to 2 months intervals and it is supposed that regional recurrences are identified and salvage surgeries are performed more quickly. Therefore, it is considered that patient survival would not be compromised with this strategy. The aim of this study was to investigate the feasibility of this strategy retrospectively.Entities:
Mesh:
Year: 2016 PMID: 26951089 PMCID: PMC4782319 DOI: 10.1186/s12885-016-2229-x
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Patient and tumor characteristics
| Bilateral RT | Unilateral RT | ||
|---|---|---|---|
| ( | ( |
| |
| Primary site | |||
| Oral cavity | 10 | 13 | 0.556 |
| Oropharynx | 12 | 8 | |
| Hypopharynx | 10 | 9 | |
| Larynx | 5 | 2 | |
| Others | 1 | 2 | |
| T-classification | |||
| T1 | 4 | 4 | 0.673 |
| T2 | 13 | 11 | |
| T3 | 5 | 4 | |
| T4 | 8 | 4 | |
| Rec | 8 | 11 | |
| rT0 | 6 | 8 | |
| rT1 | 0 | 0 | |
| rT2 | 2 | 2 | |
| rT3 | 0 | 0 | |
| rT4 | 0 | 1 | |
| N-classification | |||
| N0 | 0 | 2 | 0.124 |
| N1 | 0 | 0 | |
| N2a | 3 | 2 | |
| N2b | 18 | 17 | |
| N2c | 8 | 1 | |
| N3 | 1 | 1 | |
| Rec | 8 | 11 | |
| rN1 | 1 | 1 | |
| rN2 | 7 | 10 | |
| rN3 | 0 | 0 | |
| Stage | |||
| III | 1 | 1 | 0.637 |
| IVA | 28 | 20 | |
| IVB | 1 | 2 | |
| Rec | 8 | 11 | |
| rIII | 1 | 1 | |
| rIVA | 7 | 10 | |
| Bilateral neck LN metastasis | |||
| Yes | 9 | 1 | 0.011* |
| No | 29 | 33 | |
| Necrosis in LN | |||
| Yes | 21 | 21 | 0.401 |
| No | 14 | 9 | |
| Unknown | 3 | 4 | |
| Maximum diameter of LN (cm) | |||
| Median | 2.5 | 2.7 | 0.783 |
| Range | 0.4–7.5 | 0.8–4.1 | |
| Number of LN metastasis | |||
| 0–1 | 6 | 13 | 0.031* |
| ≥ 2 | 32 | 21 | |
| Sex | |||
| Male | 32 | 26 | 0.217 |
| Female | 6 | 8 | |
| Age | |||
| Median | 63 | 63 | 0.270 |
| Range | 38–80 | 34–84 | |
RT radiation therapy, Rec recurrence, LN lymph node. *A P value of ≤0.05 was considered statistically significant
Pathological characteristics and treatment details
| NAC | |
| Yes | 8 |
| No | 64 |
| Bi-lateral ND | |
| Yes | 26 |
| No | 46 |
| Treatment for primary lesion | |
| Surgery | 60 |
| EBRT | 9 |
| BT | 3 |
| Degree of differentiation | |
| Poorly differentiated | 20 |
| Moderately differentiated | 23 |
| Well differentiated | 15 |
| Unknown | 14 |
| Extracapsular spread | |
| Yes | 46 |
| No | 10 |
| Unknown | 16 |
| Positive/close margin | |
| Yes | 40 |
| No | 32 |
| Concurrent systemic therapy | |
| CDDP | 17 |
| Cetuximab | 2 |
| TS-1 | 2 |
| None | 51 |
| RT total dose (Gy) | |
| Median | 66 |
| Range | 60–74 |
| Radiation technique | |
| 3DCRT | 14 |
| IMRT | 58 |
RT radiation therapy, NAC neoadjuvant chemotherapy, ND neck dissection, EBRT external beam radiation therapy
BT brachytherapy, LN lymph node, 3DCRT three-dimensional conformal radiation therapy, IMRT intensity modulated radiation therapy
Fig. 1Kaplan-Meyer curves of overall survival (OS), disease-free survival (DFS), and loco-regional control (LRC)
Pattern of first failures
| Bilateral RT | Unilateral RT | ||
|---|---|---|---|
| ( | ( |
| |
| Any failure | |||
| Yes | 22 | 10 | 0.015* |
| No | 16 | 24 | |
| Loco-regional failure | |||
| Yes | 15 | 7 | 0.082 |
| No | 23 | 27 | |
| In-field failure | |||
| Yes | 8 | 2 | 0.062 |
| No | 30 | 32 | |
| Extra-field loco-regional failure | |||
| Yes | 7 | 5 | 0.572 |
| No | 31 | 29 | |
| Distant failure | |||
| Yes | 10 | 4 | 0.119 |
| No | 28 | 30 | |
RT radiation therapy. *A P value of ≤0.05 was considered statistically significant
Potential predictors influencing DFS
| 2-y DFS (%) | DFS | ||
|---|---|---|---|
| yes | no |
| |
| OC | 38.9 | 59.8 | 0.067 |
| Necrosis in LN | 63.8 | 49.1 | 0.245 |
| Bi-lateral ND | 50.3 | 54.7 | 0.654 |
| NAC | 87.5 | 48.6 | 0.076 |
| Rec | 30.6 | 59.6 | 0.062 |
| T4 | 37.5 | 56.2 | 0.21 |
| LN+ ≥2LN+ ≥2 | 44.9 | 76.5 | 0.019* |
| Extracapsular extention | 50.7 | 62.5 | 0.177 |
| Positive/close margin | 48.5 | 57.2 | 0.82 |
| Bilateral RT | 42 | 68.4 | 0.057 |
| IMRT | 69.5 | 35.7 | 0.047* |
| Systemic therapy | 38.7 | 57.1 | 0.449 |
| OC or rec | 33.9 | 66.4 | 0.013* |
| T4 or rec | 36.7 | 65.7 | 0.012* |
| OC or T4 | 37.5 | 65.1 | 0.012* |
| OC or T4 or rec | 37.9 | 72.4 | 0.006* |
DFS disease free survival
OC oral cavity, LN lymph node, ND neck dissection, Rec recurrence. *A P value of ≤0.05 was considered statistically significant
Potential predictors influencing DFS for patients excluding bilateral neck lymph node metastasis
| 2-y DFS (%) | DFS | |||||
|---|---|---|---|---|---|---|
| yes | no |
|
| HR | 95 % CI | |
| OC | 36.9 | 64.4 | 0.034* | |||
| Necrosis in LN | 64.9 | 48.4 | 0.423 | |||
| Bi-lateral ND | 53.0 | 55.9 | 0.998 | |||
| NAC | 87.5 | 48.6 | 0.076 | |||
| Rec | 30.6 | 64.2 | 0.029* | |||
| T4 | 46.7 | 56.6 | 0.398 | |||
| LN+ ≥2LN+ ≥2 | 45.3 | 76.5 | 0.032* | 0.062 | ||
| Extracapsular extention | 52.2 | 57.1 | 0.442 | |||
| Positive/close margin | 56.1 | 54.2 | 0.824 | |||
| Bilateral RT | 44.4 | 67.3 | 0.146 | |||
| IMRT | 60.8 | 33.3 | 0.050* | 0.162 | ||
| Systemic therapy | 43.3 | 56.5 | 0.619 | |||
| OC or rec | 31.9 | 74.0 | 0.004* | 0.006 | 1.696 | 1.29–1.87 |
DFS disease free survival, uni. univariate analysis, multi. multivariate analysis, HR hazard ration, CI confidence interval, OC oral cavity, LN lymph node, ND neck dissection, Rec recurrence. *A P value of ≤0.05 was considered statistically significant
Fig. 2Disease-free survival (DFS) stratified by the group of patients with oral cavity or recurrent disease or those without
Fig. 3Disease-free survival (DFS) for patients treated by unilateral neck cohort. Survival curves were stratified by the group of patients with oral cavity or recurrent disease or those without